NCT01095497View on ClinicalTrials.gov

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 7, 2010

Primary Completion Date

December 16, 2010

Study Completion Date

December 16, 2010

Conditions
Hereditary Angioedema
Interventions
BIOLOGICAL

CINRYZE

C1 esterase inhibitor (human)

Trial Locations (7)

20815

Institute for Asthma and Allergy, Chevy Chase

30342

Family Allergy and Asthma Center, Atlanta

75231

AARA Research Center, Dallas

85251

Allergy, Asthma and Immunology Associates, Scottsdale

94598

Allergy and Asthma Clinical Research, Inc., Walnut Creek

97035

Allergy, Asthma and Dermatology Research Center, Lake Oswego

99204

Marycliff Allergy Specialists, Spokane

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY

NCT01095497 - A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration | Biotech Hunter | Biotech Hunter